SMMT Summit Therapeutics PLC
Company Analysis
Latest News
🟢 Summit Therapeutics is trading 4.62% up in pre-market after Akeso reported statistically significant HARMONi-2 survival benefits
Summit Therapeutics is trading 4.62% up now at $15.27 after partner Akeso reported statistically significant overall-survival benefits for ivonescimab versus...
🟢 Summit Therapeutics is trading 4.3% up today; catalyst remains unclear
Summit Therapeutics is trading at $14.20, up 4.26%, with no new September 1, 2026 company-specific announcement or direct catalyst identified. - Recent...
🔴 Summit Therapeutics falls 4.3% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🟢 Summit Therapeutics is trading 5.76% up in pre-market after partner Akeso reported HARMONi-GI1 survival superiority
Summit Therapeutics is trading at $15.05 (+5.76%) after partner Akeso reported statistically significant overall-survival superiority in the Phase III...
Summit Partner Akeso Reports Ivonescimab Superiority in Phase III Biliary Tract Cancer Study
Summit Therapeutics announced that its partner, Akeso, Inc., reported positive topline results from the Phase III HARMONi-GI1 study. The trial, conducted in...
🟢 Summit Therapeutics is trading 10% up today after partner Akeso reported positive HARMONi-GI1 results
Summit Therapeutics is trading 10.25% up now at $14.73 after partner Akeso reported positive topline HARMONi-GI1 results on August 26, 2026. - Phase III...
Summit's Lung Cancer Drug Posts Strong Trial Data, but Can a $10 Billion Valuation Hold Without Proof It Extends Lives?
Shares of Summit Therapeutics surged 10.3% to $14.73 after The Lancet Oncology published full results from the company's flagship HARMONi trial, confirming...
🟢 Summit Therapeutics is trading 10.25% up in pre-market after positive Phase III HARMONi results
Summit Therapeutics is trading 10.25% up in pre-market at $14.73 after the August 25, 2026 publication of positive Phase III HARMONi results in The Lancet...
🟢 Summit Therapeutics is trading 4.5% up in pre-market after statistically significant HARMONi progression-free-survival improvement
Summit Therapeutics is trading 4.5% up in pre-market at $13.96 after reporting statistically significant progression-free-survival improvement from ivonescimab...
🟢 Summit Therapeutics is trading 4.9% up today after significant HARMONi trial progression-free-survival improvement
Summit Therapeutics is trading $13.35 (+4.87%) after announcing significant progression-free-survival improvement for ivonescimab plus chemotherapy versus...
🔴 Summit Therapeutics is trading 5% down today
Summit Therapeutics is trading 5.47% down now at $12.44, while the specific intraday trigger remains unclear. - No confirmed company-specific announcement has...
🟢 Summit Therapeutics is trading 5% up today in an unexplained intraday rebound
Summit Therapeutics is trading 5.03% up now at $13.13, with no confirmed company-specific catalyst identified. - No announcement, filing, earnings release, or...
🔴 Summit Therapeutics falls 4.1% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🔴 Summit Therapeutics is trading 7.23% down today after further declines from August 13 and 14
Summit Therapeutics is trading 7.23% down at $12.38 after early-session selling extended declines from August 13 and August 14. - No reliable company-specific...
🔴 Summit Therapeutics is trading 4.07% down today after opening-market selling extended August 13 decline
Summit Therapeutics is trading 4.07% down at $13.43 after opening-market selling extended the August 13 decline. - No reliable company-specific catalyst...
🔴 Summit Therapeutics is trading 5.83% down today despite Akeso’s third NMPA approval
Summit Therapeutics is trading 5.83% down now at $14.22, with no reliable company-specific negative catalyst identified for the August 13 decline. - Partner...
Summit Partner Wins China Approval for Ivonescimab, Topping Standard PD-1 Therapy
Summit Therapeutics announced that partner Akeso Inc. received marketing authorization from China’s National Medical Products Administration. The approval...
🟢 Summit Therapeutics is trading 5% up today with no clear company-specific catalyst
Summit Therapeutics is trading at $15.64, up 5.18%, with no clearly identified company-specific announcement explaining the August 11, 2026 advance. - The...
🟢 Summit Therapeutics is trading 4.48% up today with no clear catalyst
Summit Therapeutics is trading at $14.59 (+4.48%) with no clear catalyst identified. - No new company announcement, clinical update, financing, or regulatory...
Summit Therapeutics Expands Ivonescimab Program with Phase II/III Bladder Cancer Trial
Summit Therapeutics announced the expansion of its global clinical development program for its investigational bispecific antibody, ivonescimab, into...